SLDB Solid Biosciences Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1707502 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.8%
TTM EPS YoY29.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-76.9%
ROA-64.9%
ROIC (approx.)-94.0%
Asset turnover—
Leverage & solvency
Liabilities / assets12.3%
Debt / equity0.00x
Current ratio11.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $8.09M | $13.62M |
| R&D expense | $140.32M | $96.43M | $76.56M | $78.42M | $58.74M |
| SG&A expense | $38.88M | $33.30M | $27.75M | $28.95M | $27.14M |
| Operating income | -$179.21M | -$129.73M | -$104.25M | -$106.45M | -$72.25M |
| Interest expense | -$203,000 | $340,000 | $440,000 | — | — |
| Pretax income | -$174.20M | -$124.58M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$174.32M | -$124.70M | -$96.02M | -$85.98M | -$72.19M |
| EBITDA | -$177.57M | -$127.27M | -$101.67M | -$104.04M | -$69.29M |
| EPS (basic) | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 |
| EPS (diluted) | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 |
| Weighted avg. shares (diluted) | 87.50M | 40.82M | 19.88M | 8.51M | 7.12M |
| Balance sheet | |||||
| Cash & equivalents | $59.90M | $82.19M | $75.85M | $157.22M | $119.14M |
| Short-term investments | $127.95M | $68.69M | $49.62M | $58.34M | $88.64M |
| Current assets | $205.46M | $157.30M | $129.73M | $219.64M | $222.61M |
| PP&E, net | $4.17M | $4.75M | $6.62M | $9.66M | $6.46M |
| Total assets | $232.54M | $188.66M | $164.94M | $260.25M | $232.38M |
| Current liabilities | $33.47M | $30.26M | $14.52M | $22.51M | $23.60M |
| Total liabilities | $52.53M | $51.42M | $38.46M | $48.59M | $24.17M |
| Shareholders' equity | $180.01M | $137.25M | $126.48M | $211.67M | $208.21M |
| Shares outstanding | 78.97M | 40.47M | 20.39M | 19.56M | 7.36M |
| Cash flow statement | |||||
| Operating cash flow | -$156.29M | -$100.01M | -$94.18M | -$97.98M | -$77.76M |
| Capital expenditure | $1.15M | $654,000 | $1.51M | $3.02M | $1.28M |
| Free cash flow | -$157.44M | -$100.67M | -$95.69M | -$100.99M | -$79.05M |
| Investing cash flow | -$58.45M | -$16.09M | $9.69M | $59.16M | -$91.09M |
| Financing cash flow | $194.45M | $122.44M | $3.12M | $74.83M | $134.99M |
| Depreciation & amortization | $1.64M | $2.46M | $2.58M | $2.41M | $2.96M |
| Stock-based compensation | $16.91M | $10.52M | $7.62M | $7.54M | $13.37M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.